About the AMR local indicators

Data have been uploaded across six domains:

  • Supporting NHS England Initiatives
  • Antimicrobial Resistance (AMR)
  • Antibiotic Prescribing
  • Healthcare-Associated Infections (HCAI)
  • Infection Prevention and Control (IPC)
  • Antimicrobial stewardship (AMS)

Antibiotic prescribing and antibiotic resistance are inextricably linked, as overuse and incorrect use of antibiotics are major drivers of resistance. AMR local indicators are publically available data intended to raise awareness of antibiotic prescribing, AMR, HCAI, IPC and AMS; and to facilitate the development of local action plans. The data published in this tool may be used by healthcare staff, commissioners, directors of public health, academics and the public to compare the situation in their local area to the national picture.

For further information about this profile, please click here to download the user guide.

Updated indicators

July 2020 - The following indicators have been updated in the Profile: AMR Local Indicators:

Profile: AMR local indicators, Domain: Antimicrobial Stewardship Area: All Trust -

  • Percentage of single dose surgical antibiotic prophylaxis prescriptions that meet the NICE NG125 guidance regarding the choice of antibiotic for patients who have undergone elective colorectal surgery; by quarter
  • Percentage of antibiotic prescriptions for lower UTI in older people meeting NICE NG109 guidance and PHE Diagnosis of UTI guidance in terms of diagnosis and treatment: by quarter

Profile: AMR local indicators, Domain: Antibiotic Prescribing, Area: All Trusts, CCGs (since 4/2019) and GPs

  • Total antibiotic prescribing DDDs per 1000 admissions; by quarter and trust
  • Carbapenem prescribing DDDs per 1000 admissions; by quarter and acute trust
  • Proportion of total antibiotic prescribing from the "Access" category of the WHO Essential Medicines List AWaRe index; by quarter and acute trust
  • Total number of prescribed antibiotic items per STAR-PU by quarterTotal number of prescribed antibiotic items per STAR-PU by quarter
  • Total number of prescribed antibiotics items per 1000 resident individuals by quarter
  • Percentage of broad - spectrum prescribed antibiotics items (cephalosporin, quinolone and co- amoxiclav class) by quarter
  • Twelve-month rolling proportion of trimethoprim class prescribed antibiotic items as a ratio of trimethoprim to nitrofurantoin
  • Twelve-month rolling total number of prescribed antibiotic items per STAR-PU
  • Twelve-month rolling percentage of prescribed antibiotic items from cephalosporin, quinolone and co-amoxiclav class
  • Percentage of broad-spectrum prescribed antibiotic items (cephalosporin, quinolone and co-amoxiclav class) by quarter
  • Total number of prescribed antibiotic items per 1000 registered patients by quarter
  • Total number of prescribed antibiotic items per STAR-PU by quarter
  • Twelve-month rolling proportion of trimethoprim class prescribed antibiotic items as a ratio of trimethoprim to nitrofurantoin

Profile: AMR local indicators, Domain: Antimicrobial Resistance, Area: All Trust and All Clinical Commissioning Group -  

  • Percentage of E. coli blood specimens (from English laboratories) with susceptibility tests to a carbapenem; by CCG and by Quarter (2015 Q1 onwards)
  • Percentage of E. coli blood specimens (from English laboratories) with susceptibility tests to a 3rd Generation Cephalosporin (cefotaxime/ceftazidime/ceftriaxone/cefpodoxime); by CCG and by Quarter (2015 Q1 onwards)
  • Percentage of E. coli blood specimens (from English laboratories) with susceptibility tests to ciprofloxacin; by CCG and by Quarter (2015 Q1 onwards)
  • Percentage of E. coli blood specimens (from English laboratories) with susceptibility tests to gentamicin; by CCG and by Quarter (2015 Q1 onwards)
  • Percentage of E. coli blood specimens (from English laboratories) with susceptibility tests to piperacillin/tazobactam; by CCG and by Quarter (2015 Q1 onwards)
  • Rolling quarterly average proportion of E. coli blood specimens resistant to at least 1 from key antimicrobials (gentamicin, ciprofloxacin, piperacillin/tazobactam, 3rd-generation cephalosporins, carbapenems; from English laboratories); by CCG and by Quarter (2015 Q4 onwards)
  • Rolling quarterly average proportion of 'multi-drug resistant' E. coli blood specimens from key antimicrobials (gentamicin, ciprofloxacin, piperacillin/tazobactam, 3rd-generation cephalosporins, carbapenems; from English laboratories); by CCG and by Quarter (2015 Q4 onwards)
  • Rolling quarterly average proportion of 3rd generation cephalosporin resistant E. coli blood specimens (from English laboratories); by CCG and by Quarter (2015 Q4 onwards)
  • Rolling quarterly average proportion of ciprofloxacin resistant E. coli blood specimens (from English laboratories); by CCG and by Quarter (2015 Q4 onwards)
  • Rolling quarterly average proportion of gentamicin resistant E. coli blood specimens (from English laboratories); by CCG and by Quarter (2015 Q4 onwards)
  • Rolling quarterly average proportion of piperacillin/tazobactam resistant E. coli blood specimens (from English laboratories); by CCG and by Quarter (2015 Q4 onwards)
  • Percentage of E. coli blood specimens (from English laboratories) with susceptibility tests to gentamicin; by acute Trust and by Quarter (2016 Q1 onwards)
  • Percentage of E. coli blood specimens (from English laboratories) with susceptibility tests to a carbapenem; by acute Trust and by Quarter (2016 Q1 onwards)
  • Percentage of E. coli blood specimens (from English laboratories) with susceptibility tests to ciprofloxacin; by acute Trust and by Quarter (2016 Q1 onwards)
  • Percentage of E. coli blood specimens (from English laboratories) with susceptibility tests to piperacillin/tazobactam; by acute Trust and by Quarter (2016 Q1 onwards)
  • Percentage of E. coli blood specimens (from English laboratories) with susceptibility tests to a 3rd generation cephalosporin; by acute Trust and by Quarter (2016 Q1 onwards)
  • Rolling quarterly average proportion of ciprofloxacin resistant E. coli blood specimens (from English laboratories); by acute Trust and by Quarter (2016 Q1 onwards)
  • Rolling quarterly average proportion of 3rd generation cephalosporin resistant E. coli blood specimens (from English laboratories); by acute Trust and by Quarter (2016 Q1 onwards)
  • Rolling quarterly average proportion of piperacillin/tazobactam resistant E. coli blood specimens (from English laboratories); by acute Trust and by Quarter (2016 Q1 onwards)
  • Rolling quarterly average proportion of gentamicin resistant E. coli blood specimens (from English laboratories); by acute Trust and by Quarter (2016 Q1 onwards)
  • Percentage of community E. coli (or coliform) urine specimens with susceptibility tests to trimethoprim; by quarter
  • Percentage of community E. coli (or coliform) urine specimens non-susceptible to trimethoprim; by quarter
  • Percentage of community E. coli (or coliform) urine specimens with susceptibility tests to nitrofurantoin; by quarter
  • Percentage of community E. coli (or coliform) positive urine specimens non-susceptible to nitrofurantoin; by quarter

Interventions to reduce AMR

There are a number of actions that can be taken to reduce the burden of AMR. These include improved antibiotic prescribing as well as enhanced infection prevention and control, both for healthcare-associated and community-onset infections. The AMR resource handbook identifies current national policy, guidance and supporting materials in relation to antimicrobial stewardship and the infection prevention and control of healthcare associated infections in order to aid the reduction of antimicrobial resistance. 

Archived Indicators 

CQUIN Archived Indicators

Recent updates

July 2020

A pioneering scheme to provide new antibiotics to NHS patients by offering to pay pharmaceutical companies upfront for their work has started. The report is available at: https://www.gov.uk/government/news/world-first-scheme-underway-to-tackle-amr-and-protect-uk-patients 

The third WHO GLASS report (Global antimicrobial resistance and use surveillance system) of the early implementation phase, was published on 26 May. The report describes the status of development of GLASS, summarises the results of the data call on 2018 AMR data from participating countries and AMR surveillance activities globally. UK AMR data is included for 2018 for key drug-bug combinations from blood, genital, and urine specimens. The report is available at: https://www.who.int/glass/resources/publications/early-implementation-report-2020/en/

December 2019

Surveillance of surgical site infections in NHS hospitals in England annual Report for 2018 to 2019 https://www.gov.uk/government/publications/surgical-site-infections-ssi-surveillance-nhs-hospitals-in-england

Article on “Trends of antimicrobial consumption and resistance in Escherichia coli and Klebsiella pneumoniae: a segmented regression analysis of data from the European Union/European Economic Area, 2001-2018”

Article on https://www.ecdc.europa.eu/en/publications-data/surveillance-antimicrobial-resistance-europe-2018

Recent updates

July 2020

A pioneering scheme to provide new antibiotics to NHS patients by offering to pay pharmaceutical companies upfront for their work has started. The report is available at: https://www.gov.uk/government/news/world-first-scheme-underway-to-tackle-amr-and-protect-uk-patients 

The third WHO GLASS report (Global antimicrobial resistance and use surveillance system) of the early implementation phase, was published on 26 May. The report describes the status of development of GLASS, summarises the results of the data call on 2018 AMR data from participating countries and AMR surveillance activities globally. UK AMR data is included for 2018 for key drug-bug combinations from blood, genital, and urine specimens. The report is available at: https://www.who.int/glass/resources/publications/early-implementation-report-2020/en/

December 2019

Surveillance of surgical site infections in NHS hospitals in England annual Report for 2018 to 2019 https://www.gov.uk/government/publications/surgical-site-infections-ssi-surveillance-nhs-hospitals-in-england

Article on “Trends of antimicrobial consumption and resistance in Escherichia coli and Klebsiella pneumoniae: a segmented regression analysis of data from the European Union/European Economic Area, 2001-2018”

Article on https://www.ecdc.europa.eu/en/publications-data/surveillance-antimicrobial-resistance-europe-2018